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Abstract
MYC is the most altered oncogene in human cancer, and belongs to a large family of genes, including MYCN and
MYCL. Recently, while assessing the degree of correlation between MYC gene rearrangement and MYC protein
expression in aggressive B-cell lymphomas, we observed few Burkitt lymphoma (BL) cases lacking MYC protein
expression despite the translocation involving the MYC gene. Therefore, in the present study we aimed to better
characterize such cases. Our results identified two sub-groups of MYC protein negative BL: one lacking detectable MYC
protein expression but presenting MYCN mRNA and protein expression; the second characterized by the lack of both
MYC and MYCN proteins but showing MYC mRNA. Interestingly, the two sub-groups presented a different pattern of
SNVs affecting MYC gene family members that may induce the switch from MYC to MYCN. Particulary, MYCN-
expressing cases show MYCN SNVs at interaction interface that stabilize the protein associated with loss-of-function of
MYC. This finding highlights MYCN as a reliable diagnostic marker in such cases. Nevertheless, due to the overlapping
clinic, morphology and immunohistochemistry (apart for MYC versus MYCN protein expression) of both sub-groups,
the described cases represent bona fide BL according to the current criteria of the World Health Organization.
Introduction
MYC, a proto-oncogene located on chromosome 8q24,
is the most commonly altered oncogene in human can-
cer1,2. The encoded protein (MYC) is a multifunctional,
nuclear phosphoprotein that plays a key role in cell cycle
progression, apoptosis, cellular differentiation, and meta-
bolism3. It functions as a transcription factor that reg-
ulates expression of about 15% of all human genes3
through binding on enhancer box sequences (E-boxes)
and recruiting histone acetyl-transferases (HATs). In
addition to its role as a classical transcription factor,MYC
also acts to regulate global chromatin structure by mod-
ifying histone acetylation both in gene-rich regions and at
sites far from known genes4. A strict check of MYC
expression is physiologically accomplished by controlling
it at multiple levels, i.e. transcription, translation, and
mRNA and protein stability. MYC belongs to a large
family of genes, also including MYCN and MYCL1 in
human5. Despite the MYC family members display nota-
ble differences in the patterns of expression, they function
in a similar manner and have similar genomic structures.
In particular, the the MYC and MYCN loci are similarly
organized and both genes comprise three exons. Most of
the first exon and the 3′ portion of the third exon contain
untranslated regions that carry transcriptional or post-
transcriptional regulatory sequences5,6. Since, they pre-
sent high homology in their sequences and protein
binding sites and largely share their target genes, they can
compensate and substitute for each other in both phy-
siological and pathological conditions5–8. Previous studies
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demonstrated a cross regulating expression of MYC
family members; in particular, it has been shown that
MYC and MYCN reciprocally control their expression via
regulatory loops and via repressing each other at defined
promoter sites9–12.
Concerning human lymphoid neoplasms, MYC is typi-
cally expressed in Burkitt lymphoma (BL), as a con-
sequence of the t(8;14)(q24;q32) translocation or its
variants. Moreover, a variable proportion of plasmablastic
lymphomas (PBLs), diffuse large B-cell lymphomas
(DLBCLs), mantle cell lymphomas (MCLs), and plasma
cell myelomas express MYC13. In contrast, MYCN
expression has not been systematically studied so far in
lymphoid neoplasms. It has been recently shown that
MYC and MYCN are both required for hematopoietic
stem cell (HSC) proliferation, metabolic growth, differ-
entiation, long-term self-renewal activity, and survival14.
Moreover, MYCN is expressed in self-renewing, quiescent
stem cells, also including the hematopoietic ones that
switch to higher MYC expression in transit-amplifying
progenitors that further differentiate14–16.
Interestingly, in a previous study on the standardization
of MYC protein expression by immunohistochemistry
(IHC) and its correlation with MYC gene rearrangements
by fluorescent in situ hybridization (FISH) in BL and
DLBCL, we detected few BL cases lacking MYC protein
expression despite carrying a translocation involving the
MYC gene17.
Therefore, in the present study we aimed to (1) better
characterize such BL cases lacking MYC protein expres-
sion, (2) evaluate whether a cross-talk between the MYC
gene family members does also exist in BL, and (3)
explore the genetic landscape of this subset of BL cases.
Materials and methods
Cases selection, immunophenotype and FISH
We studied 92 morphologically and immunophenoty-
pically typical BL cases (82 pediatric and 10 adult; median
age: 12 years (range 3–79)). All cases have been diagnosed
according to the updated World Health Organization
(WHO) classification of tumors of haematopietic and
lymphoid tissues12. The cases were retrieved from the
archives of four institutions, namely Siena University
Hospital (Italy, n= 8), Pathodiagnostik Laboratory Berlin
(Germany, n= 4), Nairobi University (Kenya, n= 50), and
Moi University, Eldoret (Kenya, n= 30) and considering
their regional derivation by definition included 12 spora-
dic and 80 endemic samples. Before enrolling the cases in
this study, they were re-evaluated by expert hemato-
pathologists (LL, HS) and diagnoses were confirmed by
morphology on histological slides stained with haema-
toxylin and eosin (H&E) or giemsa, and by immunophe-
notyping. The main clinical features of our cohort
are summarized in Supplementary Table 1. All the
procedures were carried out automatically on repre-
sentative paraffin sections from each case by Bench Mark
Ultra (Ventana, Monza, Italy) using extended antigen
retrieval and with DAB as chromogen. MYC detection
was performed by exploiting the clone Y69 (Ventana and
Epitomics, Germany)18. For MYCN we employed the
ab198912 (Abcam, Cambridge, UK). Both antibodies
produced a strictly nuclear staining. As positive control, a
BL case expressing MYC protein at high level and char-
acterized by MYC gene rearrangement by FISH analysis,
was used; for MYCN, human brain tissue was used as
control. Negative control was provided by replacing the
two antibodies with non-immune mouse serum. The
intensity of staining and the percentage of positive neo-
plastic cells for MYC and MYCN were evaluated by two
hematopathologists (MRA and SL) independently and
scored according to previous published data17. Scoring
was evaluated on strongly stained nuclei and in hot spot
areas, if present19. FISH analysis for MYC gene rearran-
gements was performed using break-apart probes in all
cases (ZytoLight SPEC MYC Dual Color Break Apart
Probe, Bio-Optica, Germany) following the manu-
facturer’s instructions. In addition, we used dual-fusion
probes (ZytoLight SPEC MYC/IGH Dual Color Dual
Fusion Probe, Bio-Optica, Germany) in MYC transloca-
tion negative samples and in the MYC protein-negative
cases following the manufacturer’s instructions. The IGH-
MYC negative cases were further evaluated by IGK-MYC
and IGL-MYC probes (Supplementary Table 1)20. FISH
analysis of chromosome 2p24/CEP2 for MYCN amplifi-
cation [Vysis LSI MYCN (2p24) Spectrum Green/Vysis
CEP2 Spectrum Orange Probe, Abbott, USA] was also
performed as previously described21. A MYCN break
apart FISH assay was applied, containing four clones,
which flank the MYCN gene, RP11-105P20 (spectrum
green), RP11-422A6 (spectrum green), RP11-355H10
(spectrum orange) and RP11-744F11 (spectrum orange).
For each specimen, at least 100 intact non-overlapping
non nuclei were analyzed manually on a Leika DM 600B
(Leica Microsystems, Switzerland) or Zeiss fluorescence
microscope equipped with DAPI, SpectrumGreen, Spec-
trumOrange filters. DNA preparation from bacterial
clones and fluorescent labeling were performed following
recently described protocols (Supplementary Table 1)22.
Appropriate negative and positive controls were used22. In
situ hybridization (ISH) for Epstein-Barr virus encoded
RNAs (EBER) was carried out in each sample on 5mm
thick section as previously described23–25. A control slide
prepared from a paraffin-embedded tissue block con-
taining metastatic nasopharyngeal carcinoma in a lymph
node accompanied each hybridization run.
The study was approved by the institutional ethical
committees of the institutions submitting the cases, and
written permission and informed consent have been
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obtained before samples collection in accordance with the
Declaration of Helsinki.
RNA extraction
RNA was extracted from FFPE sections of primary
tumors and reactive lymph nodes using the FFPE RNA
Easy kit (Qiagen, CA), and from cell lines using the RNA
Easy Kit (Qiagen, CA), according to the manufacturer’s
instructions. The amount and quality of RNA were eval-
uated by measuring the OD at 260 nm and the 260/230
and 260/280 ratios using a Nanodrop spectrophotometer
(Celbio, Milan, Italy). The quality of RNA was also
checked using a Bioanalyzer 2100 (Agilent, CA, USA).
In situ detection of MYC and MYCN mRNA by RNAscope
assay
RNA ISH was performed to investigate the expression
of MYC gene family members at mRNA level. RNAscope
2.5 HD Red Detection Kit (Advanced Cell Diagnostics,
Hayward, CA, USA) and RNAscope Probes for MYC and
MYCN mRNA (Hs-MYC, Cat # 311761; Hs-MYCN, Cat #
417501) were applied, according to the manufacturer’s
instructions26. Briefly, sections of formalyn-fixed paraffin-
embedded (FFPE) tissue were baked for 1 h at 60 °C prior
to use. After de-paraffinization and dehydration, the tis-
sues were air dried and treated with a peroxidase blocker
before boiling in a pre-treatment solution for 10min.
Protease was then applied for 30min at 40 °C. Target
probes were hybridized for 2 h at 40 °C, followed by a
series of signal amplification and washing steps. Probes
are hybridized and followed by a cascade of signal
amplification which enhances the signal for low expres-
sing gene and mRNA present in archived samples and
partial degraded specimens. Hybridization signals were
detected by chromogenic reactions using Fast Red. mRNA
staining signal was identified as cytoplasm and nuclear red
punctate dots. Each sample was quality controlled for
mRNA integrity with a probe specific to the housekeeping
PPIB mRNA. Negative control background staining was
evaluated by using a probe specific to bacterial dapB gene;
all cases did not show any signals in the neoplastic tissue,
therefore they were included in the analysis.
Reverse transcription-quantitative PCR (RT-qPCR)
In primary tumors, the expression of MYC has been
investigated by RT-qPCR using two different approaches:
by using primers designed with the help of Primer-BLAST
service (Supplementary Table 2) and by using specific
Taqman probes forMYC gene detecting all the threeMYC
gene exons (Cat. # 4331182, ThermoFisher Scientific,
USA). This approach aimed to rule out possible technical
failures due to splicing variants in these cases. The mea-
sures obtained from all assays were used to calculate the
mean value of MYC mRNA. Thus, the resulting MYC
expression is a merge of all exons studied. MYCN mRNA
has been checked by using the specific Taqman probe
(Cat. # 4331182, ThermoFisher Scientific, USA) according
to the manufacturer’s instructions. Four endogenous
controls (hypoxanthine-guanine phosphoribosyltransfer-
ase, HPRT; Phosphoglycerate kinase, PGK; Beta-2-Micro-
globulin, b2m; TATA-Box Binding Protein, TBP) were
included in the experiment. Considering that HPRT
housekeeping gene showed the higher and more constant
expression in all our cases, we selected it for relative
quantification of each target gene.
Reactive lymph nodes have been used as control and the
relative expression is expressed as 2−ΔΔCt.
Next generation sequencing (NGS)
Targeted NGS of 409 cancer related genes was per-
formed on 40 ng tumoral DNA using the IonAmpliSeq
Comprehensive Cancer Panel (Thermo Fisher Scientific,
USA) according to the manufacturer’s protocol. Align-
ment, variant calling and filtering were performed with
Ion Reporter 4.4 (Thermo Fisher Scientific, USA). The
following filter chain was used: “Location in utr_3, spli-
cesite_3, exonic, splicesite_5, utr_5” in, “variant effect in
stoploss, nonsense, missense, frameshift Insertion, non-
frameshift Insertion, non-frameshift Block Substitution,
frameshift Deletion, non-frameshift Deletion, frameshift
Block Substitution. The base coverage was minimum
60.80% and maximum 70.36%, with average equal to
65.71%. The mean of reads with >Q20 was equal to
92.59%.
Sanger sequencing
To further explore the MYCN locus, primers were
designed to amplify 200 bp fragments covering all exons
ofMYCN gene. PCR products were purified and subjected
to Sanger sequencing in two reactions, one with the for-
ward and one with the reverse primer (Thermo Fisher
Scientific, USA, Catalog # A15629, A15630).
Functional in vitro studies
The human BL cell line Namalwa (ATCC CRL-1432)
and a human B lymphoblastoid cell line (LCL; GK-5
(ATCC® CRL-183)) were used to perform the in vitro
experiments. Namalwa was characterized by MYC-rear-
rangements and strong expression of MYC mRNA. The
LCL has been investigated to better appreciate the effect
of MYC silencing. Both cell lines were EBV-positive.
Briefly, cells were cultured in RPMI-1640 medium sup-
plemented with 10% Fetal Bovine Serum (FBS), 1%
L-glutamine, 1% penicillin/streptomycin (CARLO ERBA
Reagents, Milan, Italy), with 5% CO2, at 37 °C. Transient
transfections were performed by nucleofection, using an
Amaxa Nucleofector device (Lonza, Cologne, Germany),
program A23 and solution V (Lonza, Cologne, Germany)
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as a buffer solution, following the manufacturer’s
instructions. 5 × 106 cells were transfected with 0.5 and
1 μg small interfering RNA (siRNA) targeting MYC,
esiRNA human MYC (MISSION esiRNA Human MYC
(esiRNA1), Sigma Aldrich, St. Louis, USA) or with 1 μg
esiRNA targeting RLUC (esiRNA1) used as negative
control of gene inhibitor (MISSION esiRNA RLUC
(esiRNA1), Sigma Aldrich, St. Louis, USA); transfection
solution was used as a mock. Transfection efficiency was
assessed transfecting 2 μg of pmaxGFP and detecting both
fluorescence and cell viability by flow cytometry; RNA was
extracted 48 and 72 h after nucleofection. MYC and
MYCN expression was checked by RT-qPCR as
described above.
Statistical analyses
Statistical analyses were performed using IBM SPSS
Statistics 20.0 (IBM, Armonk, NY, USA) and Prism
(GraphPad Softwares, La Jolla, CA, USA). ANOVA,
unpaired T-tests, and linear regression were used for
continuous variable analysis. Chi-square was used for
non-continuous variable analysis. Two-sided tests were
used in all calculations. The limit of significance for all
analyses was defined as p < 0.05.
Modeling predicted effects
We annotated SNVs on MYCN and MYC canonical
amino acid sequence through Ensembl Variant Effect
Predictor (VEP)27 and graphically displayed through the
lollipos software28. We used ELM (http://elm.eu.org/)29 to
predict mutation effects on linear motives, while we
employed Mechismo (http://mechismo.russelllab.org/)30,
using default settings31 to predict mutations effects at 3D
interaction interfaces. Similarly to what we did in a pre-
vious study32, we analyzed SNVs in the exon 2 of MYC
gene for enrichment in phosphosite area, considered a
window of −/−4 aminoacids close to phosphosite resi-
dues. Frequency of observed SNVs in phosphosite was
obtained dividing the observed number of SNVs in
phosphosite area (12 and 9 for MYCN positive and
MYCN negative, respectively) for its length (n= 78), while
the expected frequency was done by dividing the total
number of SNVs (34 and 31, respectively) in exon 2 for its
length (n= 252) (Supplementary Tables 3, 4). For the
statistical analysis Fisher’s exact test was done.
Results
Rare BL cases lack MYC expression despite MYC gene
translocation
Ninety out of ninety-two cases (98%) showed a trans-
location involving MYC gene detectable by FISH analysis
(Supplementary Table 1). At immunohistochemistry,
eighty-three out of ninety-two cases (90%) did present
with intense and diffuse nuclear MYC protein expression
in more than 80% of neoplastic cells (Fig. 1a), including
the two cases lacking an identifiable MYC gene translo-
cation by commercial probes, suggesting the presence of a
MYC juxtaposition to one of the not tested light chain loci
or an alternative means of MYC activation, like cryptic
insertion of MYC into IG loci20,33–36.
Remarkably, 9/90 (7 endemic BL-eBL, 2 sporadic BL-sBL)
cases carrying a translocation involving MYC gene did not
Fig. 1 Morphology, immunophenotype and cytogenetics of our cohort. a A BL case with the typical morphology carrying MYC gene
translocation (inset) and expressing MYC at protein and mRNA level. b An example of those cases that despite MYC gene translocation (inset), did not
express MYC at protein level and showed a heterogeneous staining for MYC mRNA; these cases presented the characteristic cohesive growth,
squared-off cytoplasm and starry-sky appearance; scattered positive non-neoplastic cells (red arrows) served as internal control to ensure a successful
immunohistochemical reaction. A–B, from left to right: haematoxyin and eosin (H&E), MYC protein staining (brown chromogen; Y69 clone),
RNAscope assay for MYC mRNA (red chromogen). dapB and PPIB probes were applied as negative and positive controls, respectively. A–B, Original
magnification (O.M.): ×20.
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express MYC at the protein level, showing a weak positivity
in only 0–5% cells (Fig. 1b; Table 1). All the nine cases
presented aMYC gene translocation by break apart probes,
seven out of nine showed an MYC/IGH fusion; the 2 cases
in which the IGH/MYC fusion probes did not demon-
strated a juxtaposition of MYC to IGH, were tested by IGK
and IGL probes, revealing a translocation involving the
light chain lambda gene locus (Table 1). To evaluate
whether the lack of MYC protein observed in 9/90 cases
with MYC breakpoint was related to transcriptional or
post-transcriptional issues, MYC mRNA was investigated
by RNAscope and RT-qPCR. Strong expression of MYC
mRNA visualized as punctate red dot signals was detected
in BL cases characterized by a marked expression of MYC
protein by immunohistochemistry (Fig. 1a), whereas the
cases with the absence of MYC protein showed a hetero-
geneous staining for MYC mRNA with few cases being
almost completely negative (Fig. 1b). These findings over-
lapped the RT-qPCR results (Fig. 2) that showed a het-
erogeneous MYCmRNA level ranging from 1.98 to 6.06 for
MYC protein-positive BL cases and from 0.24 to 4.68 for
MYC protein-negative specimens (Fig. 2).
Small subset of BL cases present MYCN expression
The heterogeneous expression of MYC mRNA and
protein level in our cohort raised the question of how
cases lacking MYC mRNA and/or protein could maintainTa
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Fig. 2 Comparison of MYC protein positive with MYC protein-
negative BL cases in terms of mRNA by RT-qPCR. The merge of
measures obtained by applying different assays detecting all MYC
exons demonstrated a heterogeneous MYC mRNA expression (y axis)
among the different samples (x axis). The threshold is represented by
black dotted line. Specifically, some BL cases without MYC protein
expression showed a MYC mRNA expression overlapping that
detected in MYC protein-positive cases; whereas, others showed a
very low expression with a value below that detected in the normal
lymph node used as control (lymph node in blue, MYC protein-
positive cases in yellow, MYC protein-negative cases in green).
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a complete BL phenotype. Previous studies have demon-
strated a regulatory loop among MYC gene family
members, specifically, between MYC and MYCN9–12,37.
Accordingly, we evaluated MYCN mRNA and protein
expression in such BL cases. Interestingly, we detected an
almost mutual exclusivity between the expression of the
two genes in our series at mRNA level by RNAscope and
RT-qPCR, with cases expressing MYCN mRNA lacking
MYC mRNA and vice versa (p= 0.0003, Student’s t test,
unpaired). The regression analysis identified two different
clusters: one consisting of six cases characterized by very
low MYC mRNA level and higher MYCN mRNA
expression; the second cluster contains all the other cases,
including the typical BLs and those cases characterized by
MYC protein negativity but showing MYC mRNA
(Fig. 3a). Then we validated our results at protein level by
evaluating MYCN protein expression. A strong MYCN
nuclear staining in almost 90% of neoplastic cells was
detected in the six MYCN mRNA positive samples
(Fig. 3b) while the remaining cases showing only MYC
mRNA did not express MYCN at protein level. In such
cases we investigated all the mechanisms responsible of
MYCN over-expression (i.e. amplification, translocation
and proviral insertion)38. Specifically, by FISH analysis of
chromosome 2p24/CEP2, no amplification or transloca-
tion of the MYCN gene was detected. In addition,
sequencing of MYCN gene did not provide evidence for a
possible proviral insertion (by EBV, cytomegalovirus,
HHV8) that could explain an enhanced MYCN tran-
scription in the absence of increased copy number. We
also investigated the association with EBV by applying
EBER-ISH assay. Seventy-three cases (70 eBL, 3 sBL)
resulted EBV-positive while nineteen (10 eBL, 9 sBL) were
negative. The statistical analysis did not show a significant
difference between the MYCN negative (69% EBV-posi-
tive) and MYCN positive (66% EBV-positive) cases.
Genomic analysis supports the presence of two subsets of
BL depending on MYCN expression
We then explored the genetic landscape of eight out of
the nine MYC protein-negative cases for which enough
DNA was available by an ultra-deep sequencing analysis
targeted on 409 cancer associated genes. Since we found
SNVs affecting genes previously reported in BL and other
Fig. 3 Correlation between MYC and MYCN expression at mRNA by RT-qPCR and protein level by IHC. An almost mutual exclusivity between
MYC and MYCN was identified at mRNA and protein level. Specifically, MYCN transcript was clearly detectable almost exclusively in MYC gene/
protein-negative cases. a The regression analysis comparing the expression of MYC (x axis) and MYCN (y axis) mRNA identified two different clusters:
one consisting of six cases characterized by very low MYC mRNA level and higher MYCN mRNA expression (circle blue); the second contains all the
other cases, including the MYC translocation-positive/protein-positive samples and the cases being MYC translocation-positive/protein negative but
expressing MYC at mRNA level (circle red). The threshold is represented by black dotted line. b Immunohistochemical evaluation and RNAscope assay
for MYCN protein and mRNA expression showed a strong MYCN nuclear staining identified respectively as brown and red nuclear signals, in almost
90% of neoplastic cells only in the six MYCN mRNA positive samples. Probes detecting dapB and PPIB were used as negative and positive controls,
respectively.
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lymphomas39–46 we decide to focus our attention on the
mutational landscape of MYC family genes. Remarkably,
in cases lacking MYCN expression, we identified SNVs
only in MYC gene; specifically, we detected SNVs within
the region coding for the N-terminus domain (NTD) of
MYC. In particular, we reported SNVs in the MYC gene
resulting in amino acid changes at position 27
(chr8:128,750,543A>C, p.Y27S; chr8:128,750,543A>G,
p.Y27C; chr8:128,750,542T>G, p.Y27D) of the MYC
protein (Supplemenatry Table S3). It is likely that these
Myc amino-terminal region HLH
3 31 58 84 133 156 261 293 334 361 408 431 464
MYCN MYC
MYCN MYC
H431Y
T427I
V421I
A418T
V408M
R381K
Disabling
Enabling
Mixed (both enabling and disabling)
MAX MAX
MNT
MYC
A
B
C
non-synonymous mutation
phosphorylation site
acetylation site
ubiquitination site
P406L
V409I
A414T
Degradation NLS
Interactome
DNA DNA
Myc amino-terminal region HLH Myc-LZ
2 10 19 29 38 46 58 66 74 102 134 143 151 161 170 178 188 196 207 225 234 243 252 260 268 277 285 293 307 317 326 334 343 355 366 389 399 412 439
Fig. 4 MYC and MYCN non-synonymous mutations comparison. Mutations (red lollipops) annotated on protein primary sequence with
additional information regarding post-translational modifications (PTMs) and domain composition. Linear motif annotations have been obtained
from ELM (http://elm.eu.org/cgimodel.py?fun=smartResult&userId=QiKSrcdQR9&EXPECT_CUTOFF=100&r=1&bg=on). MYC mutations have been
mapped to the canonical (isoform 1 from Swissprot, ID: P01106) protein isoform. Only mutations for MYCN positive cases are displayed. b Network
representation of predicted effects at 3D interaction interfaces through Mechismo (http://mechismo.russelllab.org/). Predicted disabling, enabling
and mixed effects are in indicated by red, green and orange arrows. c 3D cartoon representation (PDB ID: 1NKP) of mutations perturbing interaction
interfaces. Sphere coloring is the same as for arrows in B. For MYC, we show mutation numberings referred to both the canonical amino acid
sequence as well as to the isoform 2.
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SNVs, adjacent to N11 polymorphism and within the Y69
target epitope, may interfere with antibody binding and
explain the MYC protein-negative staining.
On the other hand, MYCN positive samples, carried
MYCN SNVs concentrated at the N-and C-terminus of
the MYC amino-terminal region and at the helix-loop-
helix (HLH) domain (Fig. 4a), where they likely perturb
regulatory or functional motives of the protein. Indeed,
while the first region (a.a. 20–90) is a segment important
for post-translational modifications (PTMs) and binding
events (e.g. GSK3, p38 MAPK, WW binding domains and
FBXW7) leading to MYCN degradation47, the second one
(approximately a.a. 300–370), contains nuclear localiza-
tion sequences (NLSs) (Fig. 4a; http://elm.eu.org/). The
overall electrostatic charge switch caused by non-
synonymous mutations in MYCN, with nearly 40% of
SNVs leading to an increase of positive charge (Supple-
mentary Table 3), is likely to affect the binding and sig-
naling properties mediated by these motives. Along this
line, SNVs affecting the C-terminal HLH domain are
predicted to positively affect MYCN interactome in these
cases, in contrast to MYC, which is overall disabled
(Fig. 4b, c). Taken together, MYCN mutations in MYCN
expressing cases are predicted to lead to an overall sta-
bilization of its activity, by ultimately perturbing degra-
dation signals while enhancing nuclear localization and
mediated interactions. Interestingly, we found no sig-
nificant enrichment of SNVs in MYC’s exon 2 phospho-
site regions (Supplemetary Tables 3, 4), which is a
hallmark of MYC up-regulation in sporadic BL32. Finally,
to further support the hypothesis of a cross-talk between
MYC and MYCN in BL, we silenced MYC gene in BL
Namalwa and LCLs cell lines by shRNA and evaluated
MYCN mRNA and protein expression after 48 and 72 h.
We found that silencing of MYC gene results in higher
expression of both MYCN mRNA and protein (Fig. 5a).
Particularly, after siRNA nucleofection, MYC mRNA
levels in Namalwa cell line dropped down from 40.79
arbitrary units (AU) to 11.03 AU at 48 h and 12.11 AU at
72 h, while MYCN increased from 0 to 15.2 at 48 and
13.89 at 72 h (p < 0.0001). In LCLs cell line MYC dropped
down from 30.5 to 8.28 at 48 h and 8.75 at 72, while
MYCN raised from 0.75 to 12.9 and 12.26 (48 and 72 h
respectively). Consistently, MYCN protein expression was
recorded after transfection by RT-qPCR (Fig. 5b).
Discussion
In this paper we describe a rare subset of BL cases
characterized by the lack of MYC protein expression and
the presence of MYCN protein. These rare cases, despite
FISH analysis documenting MYC gene translocation to
one of the immunoglobulin loci, lacked MYC protein
expression and expressed another MYC family member,
MYCN. Noteworthy, we observed an inverse correlation
between the expression of MYC and MYCN at mRNA
and protein level. It has been previously demonstrated
that MYCN is able to compensate MYC activity in neu-
roblastoma cell lines and primary tumors, a mutual reg-
ulatory loop existing between them7–13. NGS analysis
showed a different mutational fingerprint of MYC family
genes in cases expressing or not MYCN at mRNA and
protein level. Specifically,MYCN negative cases presented
Fig. 5 Regulatory loop between MYC and MYCN exists also in Namalwa and lymphoblastoid cell lines. a Silencing of MYC mRNA expression
by siRNA nucleofection in Namalwa and lymphoblastoid (B) cell lines resulted in a lower expression of MYC mRNA along with higher expression of
MYCN. MYC mRNA has been investigated by RT-qPCR applying designed and Taqman primers. b Transfected cells collected after MYC silencing
showed MYCN protein expression by immunohistochemistry.
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SNVs in MYC genes localized within the region coding for
the NTD. It is conceivable that such SNVs prevented an
effective antigen-antibody reaction, as recently reported34,
thus determining the negative results at immunohis-
tochemistry. By contrast, in MYCN positive samples ana-
lysis of MYCN SNVs at linear motives and interaction
interfaces suggests converging effects towards an overall
stabilization of protein activity, by either perturbation of
degradation signals, enhancement of nuclear localization,
or interactome stabilization. On the other hand, multiple
somatic mutations affecting MYC suggest an overall loss-
of-function phenotype, differently from sporadic BL, where
SNVs cluster at exon 2 phosphosite regions leading to
MYC up-regulation32. It is intriguing to speculate that the
SNVs present in MYC and MYCN in the respective cases
may activate and switch on MYCN gene and simulta-
neously switch off MYC gene by inducing their regulatory
loop48. Interestingly, we found that silencing of MYC gene
results in higher expression of both MYCN mRNA and
protein. In particular, after siRNA nucleofection, MYC
mRNA levels decreased while MYCN ones increased and
MYCN protein expression was detectable in cell lines.
In conclusion, it is conceivable that MYCN determined
molecular effects, in terms of transcriptional regulation,
similar to those exerted by MYC in BL cells thanks to a
cross-talk between the two genes involving a significant
number of targets shared by MYC and MYCN9–11,15,16.
This mirrors what is already known in neuroblastoma cell
lines and primary tumors in which the expression of MYC
and MYCN are mutually exclusive9,11,15,16. Remarkably,
we have yet only detected the switch from MYC to MYCN
expression in MYC-translocation-positive BL in the
pediatric age group and only in eBL. Nevertheless, the
genetic composition of the tumors suggests that the switch
occurs in the presence and probably subsequently
to the IG-MYC translocation. Therefore and considering
that the clinical presentation, morphologic appearance
and immunohistochemical profile of these MYC
protein negative/MYCN protein-positive MYC-translo-
cated tumors is not different from MYC protein-positive
BL we think that this does not affect the diagnostic work-
up as such cases might be easily diagnosed as BL based on
current WHO criteria13.
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